Table 4.

IL-8 -251 T > A polymorphism and the risk of gastroduodenal diseases

Genotype	Disease group	Unadjusted OR (95% CI) by univariate analysis	p	Adjusted OR (95% CI) by multivariate analysis	p
T/A (heterozygote)	Hp(+) NAG (n = 49)	0.74 (0.45–1.22)	0.2406	0.76 (0.46–1.29)	0.3018
	Hp(+) mild AG (n = 27)	1.06 (0.55–2.05)	0.8581	1.09 (0.55–2.16)	0.8052
	Hp(+) severe AG (n = 37)	1.94 (0.99–3.82)	0.0549	2.06 (1.01–4.21)	0.0471
	Hp(−) DU(n = 3)	0.79 (0.15–4.02)	0.7729	0.84 (0.16–4.36)	0.8342
	Hp(+) DU (n = 73)	0.71 (0.45–1.11)	0.1297	0.80 (0.50–1.29)	0.3616
	Hp(−) GC(n = 46)	1.57 (0.87–2.84)	0.1326	1.66 (0.89–3.07)	0.1058
	Hp(+) GC (n = 122)	1.65 (1.06–2.58)	0.0257	1.71 (1.07–2.72)	0.0252
A/A (mutant)	Hp(+) NAG (n = 7)	0.55 (0.21–1.43)	0.2237	0.59 (0.21–1.59)	0.2952
	Hp(+) mild AG (n = 5)	1.03 (0.34–3.14)	0.9593	1.00 (0.31–3.17)	0.9941
	Hp(+) severe AG (n = 9)	2.47 (0.93–6.59)	0.0710	2.42 (0.85–6.84)	0.0966
	Hp(−) DU (n = 1)	1.37 (0.13–14.03)	0.7895	1.66 (0.16–17.71)	0.6743
	Hp(+) DU (n = 14)	0.71 (0.33–1.55)	0.3905	0.72 (0.32–1.63)	0.4289
	Hp(−) GC (n = 7)	1.25 (0.46–3.40)	0.6577	1.19 (0.43–3.34)	0.7403
	Hp(+) GC (n = 27)	1.92 (0.95–3.86)	0.0683	1.94 (0.93–4.06)	0.0744
T/A + A/A (A carrier)	Hp(+) NAG (n = 56)	0.71 (0.44–1.15)	0.1669	0.73 (0.44–1.22)	0.2282
	Hp(+) mild AG (n = 32)	1.06 (0.56–1.99)	0.8651	1.07 (0.55–2.08)	0.8336
	Hp(+) severe AG (n = 46)	2.03 (1.05–3.90)	0.0351	2.12 (1.06–4.25)	0.0335
	Hp(−) DU (n = 4)	0.88 (0.19–4.05)	0.8703	0.96 (0.20–4.48)	0.3066
	Hp(+) DU (n = 87)	0.71 (0.46–1.09)	0.1152	0.79 (0.50–1.24)	0.3035
	Hp(−) GC (n = 53)	1.52 (0.86–2.70)	0.1524	1.58 (0.87–2.87)	0.1346
	Hp(+) GC (n = 149)	1.70 (1.11–2.60)	0.0155	1.74 (1.11–2.74)	0.0161

The control was regarded as the reference subject group, and the T/T wild type was considered as the reference genotype